JP2005530814A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005530814A5 JP2005530814A5 JP2004509678A JP2004509678A JP2005530814A5 JP 2005530814 A5 JP2005530814 A5 JP 2005530814A5 JP 2004509678 A JP2004509678 A JP 2004509678A JP 2004509678 A JP2004509678 A JP 2004509678A JP 2005530814 A5 JP2005530814 A5 JP 2005530814A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- disease
- quinuclidine
- condition
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 201000010099 disease Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 9
- 238000000034 method Methods 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- -1 trifluoromethoxy, cyano, amino Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 3
- 206010010904 Convulsion Diseases 0.000 claims 3
- 206010049119 Emotional distress Diseases 0.000 claims 3
- 230000009429 distress Effects 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- UANSQQFYKHHDJM-KRWDZBQOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]naphthalene-1-carboxamide Chemical compound C1=CC=C2C(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC=CC2=C1 UANSQQFYKHHDJM-KRWDZBQOSA-N 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000032841 Bulimia Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- MNEAITWEUWOECE-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)-2-(trifluoromethyl)benzimidazole Chemical compound C1N(CC2)CCC2C1N1C2=CC=CC=C2N=C1C(F)(F)F MNEAITWEUWOECE-UHFFFAOYSA-N 0.000 claims 1
- ASZBYFJRDZMPKW-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)-5-(trifluoromethyl)benzimidazole Chemical compound C1N(CC2)CCC2C1N1C2=CC=C(C(F)(F)F)C=C2N=C1 ASZBYFJRDZMPKW-UHFFFAOYSA-N 0.000 claims 1
- FHGRWVDBARLWBG-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)benzimidazole Chemical compound C1=NC2=CC=CC=C2N1C(C1)C2CCN1CC2 FHGRWVDBARLWBG-UHFFFAOYSA-N 0.000 claims 1
- HZINIPZXUWIZML-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)benzotriazole Chemical compound N1=NC2=CC=CC=C2N1C(C1)C2CCN1CC2 HZINIPZXUWIZML-UHFFFAOYSA-N 0.000 claims 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 206010002660 Anoxia Diseases 0.000 claims 1
- 241000976983 Anoxia Species 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 108010009685 Cholinergic Receptors Proteins 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000026097 Factitious disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000010886 Peripheral nerve injury Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 208000005374 Poisoning Diseases 0.000 claims 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims 1
- 208000005107 Premature Birth Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 206010052276 Pseudodementia Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000022372 Reading disease Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 102000034337 acetylcholine receptors Human genes 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000007953 anoxia Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010013932 dyslexia Diseases 0.000 claims 1
- 210000000750 endocrine system Anatomy 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000002650 habitual effect Effects 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 230000029849 luteinization Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 206010036596 premature ejaculation Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000020341 sensory perception of pain Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 230000016160 smooth muscle contraction Effects 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200200834 | 2002-05-30 | ||
| PCT/DK2003/000354 WO2003101987A1 (en) | 2002-05-30 | 2003-05-27 | 3-substituted quinuclidines and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005530814A JP2005530814A (ja) | 2005-10-13 |
| JP2005530814A5 true JP2005530814A5 (https=) | 2006-07-06 |
Family
ID=29594980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004509678A Withdrawn JP2005530814A (ja) | 2002-05-30 | 2003-05-27 | ３−置換されたキヌクリジン類及びその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7332507B2 (https=) |
| EP (1) | EP1513839B1 (https=) |
| JP (1) | JP2005530814A (https=) |
| CN (1) | CN1656093A (https=) |
| AT (1) | ATE334129T1 (https=) |
| AU (1) | AU2003227522A1 (https=) |
| CA (1) | CA2482639A1 (https=) |
| DE (1) | DE60307102T2 (https=) |
| MX (1) | MXPA04011858A (https=) |
| NZ (1) | NZ536197A (https=) |
| WO (1) | WO2003101987A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05003317A (es) | 2002-09-25 | 2005-07-05 | Memory Pharm Corp | Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos. |
| RU2389729C2 (ru) | 2003-12-22 | 2010-05-20 | Мемори Фармасьютиклз Корпорейшн | 1н-индазолы, 1, 2-бензизоксазолы и 1, 2-бензизотиазолы, их получение и применение |
| EP1735306A2 (en) | 2004-03-25 | 2006-12-27 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
| CA2567977A1 (en) | 2004-04-22 | 2006-01-05 | Memory Pharmaceutical Corporation | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof |
| NZ551712A (en) | 2004-05-07 | 2010-07-30 | Memory Pharm Corp | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparations and uses thereof |
| AR050253A1 (es) | 2004-06-24 | 2006-10-11 | Smithkline Beecham Corp | Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento |
| CA2591817A1 (en) | 2004-12-22 | 2006-06-29 | Memory Pharmaceuticals Corporation | Nicotinic alpha-7 receptor ligands and preparation and uses thereof |
| US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
| PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
| WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
| CN110845491B (zh) * | 2018-08-21 | 2022-05-13 | 鲁南制药集团股份有限公司 | 一种异丙托溴铵晶体 |
| CN110845492B (zh) * | 2018-08-21 | 2022-05-13 | 鲁南制药集团股份有限公司 | 一种异丙托溴铵一水合物 |
| CN113121522A (zh) * | 2019-12-30 | 2021-07-16 | 武汉先路医药科技股份有限公司 | 一种异丙托溴铵晶体及其制备方法 |
| CN116785286B (zh) * | 2020-10-10 | 2026-02-17 | 远大医学营养科学(武汉)有限公司 | 戊乙奎醚在治疗或预防视力损伤性眼部疾病中的用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4009565A1 (de) * | 1990-03-24 | 1991-09-26 | Merck Patent Gmbh | Indolderivate |
| SE9201478D0 (sv) | 1992-05-11 | 1992-05-11 | Kabi Pharmacia Ab | Heteroaromatic quinuclidinenes, their use and preparation |
| SE9904176D0 (sv) | 1999-11-18 | 1999-11-18 | Astra Ab | New use |
| DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
| KR100823908B1 (ko) * | 2000-10-20 | 2008-04-21 | 바이오비트럼 에이비(피유비엘) | 2-, 3-, 4-, 또는 5-치환-ｎ1-(벤젠술포닐)인돌 및 이의치료 용도 |
| ATE385497T1 (de) * | 2000-12-01 | 2008-02-15 | Neurosearch As | 3-substituierte quinuclidin-derivate und deren verwendung als nikotinischen agonisten |
| DE10121215A1 (de) * | 2001-04-30 | 2002-10-31 | Merck Patent Gmbh | Dihydro-imidazo[4,5-e]indol- und 7H-Pyrrolo[3,2-f]chinoxalin Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden |
| DE10121217A1 (de) * | 2001-04-30 | 2002-10-31 | Merck Patent Gmbh | 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden |
-
2003
- 2003-05-27 CN CNA038123258A patent/CN1656093A/zh active Pending
- 2003-05-27 WO PCT/DK2003/000354 patent/WO2003101987A1/en not_active Ceased
- 2003-05-27 MX MXPA04011858A patent/MXPA04011858A/es active IP Right Grant
- 2003-05-27 CA CA002482639A patent/CA2482639A1/en not_active Abandoned
- 2003-05-27 AU AU2003227522A patent/AU2003227522A1/en not_active Abandoned
- 2003-05-27 DE DE60307102T patent/DE60307102T2/de not_active Expired - Lifetime
- 2003-05-27 JP JP2004509678A patent/JP2005530814A/ja not_active Withdrawn
- 2003-05-27 US US10/512,570 patent/US7332507B2/en not_active Expired - Fee Related
- 2003-05-27 AT AT03724901T patent/ATE334129T1/de not_active IP Right Cessation
- 2003-05-27 NZ NZ536197A patent/NZ536197A/en not_active IP Right Cessation
- 2003-05-27 EP EP03724901A patent/EP1513839B1/en not_active Expired - Lifetime
-
2007
- 2007-12-20 US US12/004,022 patent/US20080132704A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005524713A5 (https=) | ||
| JP2005530814A5 (https=) | ||
| JP2009538867A5 (https=) | ||
| EP1532144B1 (en) | quinuclidine derivatives and their use | |
| JP2006508109A5 (https=) | ||
| JP2009526814A5 (https=) | ||
| RU2008139481A (ru) | Новые 1,4-диаза-бицикло[3.2.2]нонил-оксадиазолильные производные и их медицинское применение | |
| JP2009537599A5 (https=) | ||
| EP1866314B1 (en) | Novel diazabicyclic aryl derivatives and their medical use | |
| JP2004538268A5 (https=) | ||
| JP2009538870A5 (https=) | ||
| JP2009538869A5 (https=) | ||
| JP2009526814A (ja) | 鏡像異性的に純粋なキヌクリジニルオキシピリダジン、及びニコチン性アセチルコリン受容体リガンドとしてのその使用 | |
| JP2008530171A5 (https=) | ||
| EP1863819A2 (en) | Diazabicyclic aryl derivatives and their use as chinolinergic ligands at the nicotinic acetylcholine receptors | |
| EP1713809B1 (en) | Dimeric azacyclic compounds and their use | |
| JP2009526776A5 (https=) | ||
| JP2006503062A5 (https=) | ||
| JP2007530635A5 (https=) | ||
| JP2005524712A5 (https=) | ||
| JP2009537598A5 (https=) | ||
| MX2011001070A (es) | Nuevos derivados de difenil 1,2,3-triazol utiles como moduladores de los receptores de acetilcolina nicotinicos. | |
| JP2008526706A5 (https=) | ||
| RU2010135037A (ru) | Новые производные, 1,4-диазабицикло[3.2.2]нонилоксадиазолил, полезные в качестве модуляторов никотиновых ацетилхолиновых рецепторов | |
| JP2006517567A5 (https=) |